Bornstein Jonathan

SEC source: 0001899287-25-000003 · wk-form4_1741814092.xml · derivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 3,471 shares

Expires 2025-03-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001899287-25-000003 · wk-form4_1741814092.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 422,668

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 419,197 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-25-000002 · wk-form4_1740443834.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,197

F1 · kind: This transaction was effected pursuant to non-discretionary, sell-to-cover arrangements mandated by the issuer to fund tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.06 to $3.215, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: These securities are restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000021 · wk-form4_1732310861.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 454,131

F6 · kind: This transaction was effected pursuant to non-discretionary, sell-to-cover arrangements mandated by the issuer to fund tax withholding obligations in connection with the vesting of restricted stock units.

F7 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.93 to $2.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F8 · balance_after: These securities are restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000021 · wk-form4_1732310861.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,040,950

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5 · balance_after: Includes 16,763 shares of the issuer's common stock previously held directly by the reporting person, which were transferred on November 21, 2024 to the Jonathan G. Bornstein and Phyllis S. Brock Trust Agreement, for which the reporting person and his spouse are co-trustees.

F3 · ownership.nature: The securities are held directly by Jonathan G. Bornstein and Phyllis S. Brock Trust Agreement, for which the reporting person and his spouse are co-trustees.

SEC source: 0001942459-24-000021 · wk-form4_1732310861.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,039,187

F1 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.89 to $1.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · balance_after: These shares of the issuer's common stock, which were previously held directly by the reporting person, were transferred on September 30, 2024 to the Jonathan G. Bornstein and Phyllis S. Brock Trust Agreement, for which the reporting person and his spouse are co-trustees.

F3 · ownership.nature: The securities are held directly by Jonathan G. Bornstein and Phyllis S. Brock Trust Agreement, for which the reporting person and his spouse are co-trustees.

SEC source: 0001628280-24-043858 · wk-form4_1729895682.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,768

Underlying: Common stock · 27,768 shares

Expires 2027-03-15

F3 · kind: In connection with the Liquidating Distribution, the Issuer assumed Amprius Holdings' outstanding options to purchase shares of Amprius Holdings' Class A common stock (the "Holdings Options") granted under the Amprius, Inc. 2008 Stock Plan and the Amprius, Inc. Second Equity Incentive Plan (the "Option Assumption"). As a result of the Option Assumption, each Holdings Option held by the Reporting Person became an option to purchase a number of shares of the Issuer's common stock, subject to certain adjustments to the terms of such options to comply with the requirements of U.S. Internal Revenue Code treasury regulation relating to equity grant assumptions.

F6 · price: Received in connection with the Option Assumption in exchange for stock options to acquire 40,000 shares of Amprius Holdings' Class A common stock at an exercise price of $0.43 per share.

F4 · derivative.exercise_date: The options are fully vested.

SEC source: 0001628280-24-043858 · wk-form4_1729895682.xml · derivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,471

Underlying: Common stock · 3,471 shares

Expires 2025-03-17

F3 · kind: In connection with the Liquidating Distribution, the Issuer assumed Amprius Holdings' outstanding options to purchase shares of Amprius Holdings' Class A common stock (the "Holdings Options") granted under the Amprius, Inc. 2008 Stock Plan and the Amprius, Inc. Second Equity Incentive Plan (the "Option Assumption"). As a result of the Option Assumption, each Holdings Option held by the Reporting Person became an option to purchase a number of shares of the Issuer's common stock, subject to certain adjustments to the terms of such options to comply with the requirements of U.S. Internal Revenue Code treasury regulation relating to equity grant assumptions.

F5 · price: Received in connection with the Option Assumption in exchange for stock options to acquire 5,000 shares of Amprius Holdings' Class A common stock at an exercise price of $0.68 per share.

F4 · derivative.exercise_date: The options are fully vested.

SEC source: 0001628280-24-038255 · wk-form4_1724360638.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,528,251

F1 · kind: This transaction was effected pursuant to non-discretionary, sell-to-cover arrangements mandated by the issuer to fund tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.03 to $1.0523, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 489,064 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000015 · wk-form4_1716599100.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,546,895

F1 · kind: This transaction was effected pursuant to non-discretionary, sell-to-cover arrangements mandated by the issuer to fund tax withholding obligations in connection with the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.3824, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · balance_after: Includes 523,997 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000015 · wk-form4_1716599100.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,555,626

F1 · kind: This transaction was effected pursuant to non-discretionary, sell-to-cover arrangements mandated by the issuer to fund tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.345, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000011 · wk-form4_1713218014.xml · derivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1

Underlying: Common stock · 1,007,867 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001942459-24-000011 · wk-form4_1713218014.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,566,797

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 558,930 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000009 · wk-form4_1712175188.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,007,868

Underlying: Common stock · 125,983 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000009 · wk-form4_1712175188.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 558,930

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.29 to $2.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 558,930 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000009 · wk-form4_1712175188.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 684,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001628280-24-011985 · wk-form4_1710891126.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 558,930

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of the issuer's common stock. 1/16th of shares subject to award will vest on May 20, 2024 and quarterly thereafter on each August 20, November 20, February 20 and May 20, subject to the reporting person's continued service on each such date, until the award is fully vested on February 20, 2028.

F2 · balance_after: Includes 558,930 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · derivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,133,851

Underlying: Common stock · 40,200 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · derivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,174,051

Underlying: Common stock · 109,800 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.87 to $3, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,283,851

Underlying: Common stock · 150,000 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.04 to $4.58, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · derivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,433,851

Underlying: Common stock · 150,000 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,366

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.96 to $4.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 9

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,583,851

Underlying: Common stock · 54,477 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 8

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,638,328

Underlying: Common stock · 47,767 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.91 to $4.135, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 7

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,686,095

Underlying: Common stock · 47,756 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,733,851

Underlying: Common stock · 27,631 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.76 to $4.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 9

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,761,482

Underlying: Common stock · 49,508 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.72 to $3.08, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 8

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,810,990

Underlying: Common stock · 48,052 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 7

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,859,042

Underlying: Common stock · 24,809 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.12 to $3.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.